CBS promoter hypermethylation increases the risk of hypertension and stroke
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/157898 |
Resumo: | OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients. |
id |
USP-19_27dc0360185a46528e4d84d226313b27 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/157898 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
CBS promoter hypermethylation increases the risk of hypertension and strokeCBSHypermethylationHypertensionStrokeHomocysteineOBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-05-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/15789810.6061/clinics/2019/e630Clinics; Vol. 74 (2019); e630Clinics; v. 74 (2019); e630Clinics; Vol. 74 (2019); e6301980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/157898/153187https://www.revistas.usp.br/clinics/article/view/157898/153589Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessWang, ChangyiXu, GuodongWen, QiPeng, XiaolinChen, HongenZhang, JingwenXu, ShanZhang, ChunhuiZhang, MinMa, JianpingHui, ZhaohuiWu, GuifuMa, Min2019-05-24T13:16:00Zoai:revistas.usp.br:article/157898Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-24T13:16Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
title |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
spellingShingle |
CBS promoter hypermethylation increases the risk of hypertension and stroke Wang, Changyi CBS Hypermethylation Hypertension Stroke Homocysteine |
title_short |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
title_full |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
title_fullStr |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
title_full_unstemmed |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
title_sort |
CBS promoter hypermethylation increases the risk of hypertension and stroke |
author |
Wang, Changyi |
author_facet |
Wang, Changyi Xu, Guodong Wen, Qi Peng, Xiaolin Chen, Hongen Zhang, Jingwen Xu, Shan Zhang, Chunhui Zhang, Min Ma, Jianping Hui, Zhaohui Wu, Guifu Ma, Min |
author_role |
author |
author2 |
Xu, Guodong Wen, Qi Peng, Xiaolin Chen, Hongen Zhang, Jingwen Xu, Shan Zhang, Chunhui Zhang, Min Ma, Jianping Hui, Zhaohui Wu, Guifu Ma, Min |
author2_role |
author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Wang, Changyi Xu, Guodong Wen, Qi Peng, Xiaolin Chen, Hongen Zhang, Jingwen Xu, Shan Zhang, Chunhui Zhang, Min Ma, Jianping Hui, Zhaohui Wu, Guifu Ma, Min |
dc.subject.por.fl_str_mv |
CBS Hypermethylation Hypertension Stroke Homocysteine |
topic |
CBS Hypermethylation Hypertension Stroke Homocysteine |
description |
OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-10 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/157898 10.6061/clinics/2019/e630 |
url |
https://www.revistas.usp.br/clinics/article/view/157898 |
identifier_str_mv |
10.6061/clinics/2019/e630 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/157898/153187 https://www.revistas.usp.br/clinics/article/view/157898/153589 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 74 (2019); e630 Clinics; v. 74 (2019); e630 Clinics; Vol. 74 (2019); e630 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222764108349440 |